Taking Target
The immune system has a tough time targeting cancer cells because they often find ways to alter their make-up or microenvironment to avoid detection. To overcome this, researchers at Meyer Cancer Center and elsewhere have found ways to help the immune system recognize cancer cells and strengthen its response so that it will destroy them. Find out about the innovative ways that physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian are harnessing patients' own bodies to target their tumors.
Radiotherapy
From foe to friend: Transforming tumors into personalized vaccines
Radiation has long been a pillar of cancer care, alongside surgery and chemotherapy. But what if it could be used in a new way - to trigger a set of immune responses that transform tumors into killing machines, a type of in situ vaccine?
Blood cancers
Teaming up to translate AML discoveries into novel immunotherapy
Weill Cornell Medicine and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The company is working with Gail Roboz, M.D., as they develop gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor.
Pancreatic cancer
Eliminating T cell barriers in pancreatic cancer patients
Immunotherapeutic approaches that have worked in other cancer types have not been effective against pancreatic cancer. Douglas Fearon, M.D., is hoping to change that by exploring ways to eliminate T cell barriers in pancreatic cancer patients.
Ovarian cancer
Ovarian Cancer: Overcoming Obstacles to Immunotherapy
Juan R. Cubillos-Ruiz, Ph.D., and Eloise Chapman-Davis, M.D., are trying to make immunotherapy treatments work for ovarian cancer patients.
Genitourinary cancer
Immunotherapy in genitourinary cancers
Is there anything that can be done to increase the viability of immunotherapy in prostate cancer? Mark A Rubin, M.D., discusses the issue of "mutation load" in various genitourinary cancers.
